Description: International Stem Cell Corporation (ISCO) is a biotechnology company. The Company is focused on therapeutic and biomedical product development. The Company's segments include Therapeutic Market, Cosmetic Market and Biomedical Market. The Company's subsidiaries include International Stem Cell Corporation, a research and development company, for the Therapeutic Market for clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases, such as Parkinson's disease, liver diseases and corneal blindness; Cyto Therapeutics, PTY LTD, a research and development company, for the Therapeutic Market; Lifeline Skin Care, Inc. for the Cosmetic Market, which develops, manufactures and markets a category of cosmetic skin care products based on biotechnology with human stem cells, and Lifeline Cell Technology, LLC for the Biomedical Market, which develops, manufactures and commercializes primary human cell research products.
Home Page: www.internationalstemcell.com
9745 Businesspark Avenue
San Diego,
CA
92131
United States
Phone:
760 940 6383
Officers
| Name | Title |
|---|---|
| Dr. Andrey Semechkin Ph.D. | Co-Chairman & CEO |
| Dr. Russell Kern Ph.D. | Exec. VP, Chief Scientific Officer, Principal Financial Officer & Director |
| Ms. Rebecca McGee M.B.A. | Pres of Lifeline Cell Technology |
Exchange: OTCQX
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0.195 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 26 |